These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31222044)

  • 1. Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study.
    Yokoyama K; Fukagawa M; Akiba T; Nakayama M; Ito K; Hanaki K; Wolf M; Hirakata H
    Sci Rep; 2019 Jun; 9(1):8877. PubMed ID: 31222044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study.
    Ito K; Yokoyama K; Nakayama M; Fukagawa M; Hirakata H
    BMC Nephrol; 2021 Nov; 22(1):374. PubMed ID: 34758731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width.
    Ito K; Yokoyama K; Nakayama M; Fukagawa M; Hirakata H
    Sci Rep; 2022 Feb; 12(1):2406. PubMed ID: 35165297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
    Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
    Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
    Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.
    Umanath K; Jalal DI; Greco BA; Umeukeje EM; Reisin E; Manley J; Zeig S; Negoi DG; Hiremath AN; Blumenthal SS; Sika M; Niecestro R; Koury MJ; Ma KN; Greene T; Lewis JB; Dwyer JP;
    J Am Soc Nephrol; 2015 Oct; 26(10):2578-87. PubMed ID: 25736045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data.
    Rodby RA; Umanath K; Niecestro R; Bond TC; Sika M; Lewis J; Dwyer JP;
    Drugs R D; 2015 Sep; 15(3):271-9. PubMed ID: 26239948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia.
    Ito K; Akizawa T; Arita K; Mitobe Y; Komatsu N
    Clin Exp Nephrol; 2024 Jul; 28(7):636-646. PubMed ID: 38402503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model.
    Brunelli SM; Sibbel SP; Van Wyck D; Sharma A; Hsieh A; Chertow GM
    Drugs R D; 2017 Mar; 17(1):159-166. PubMed ID: 28078600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Sucroferric Oxyhydroxide on Fibroblast Growth Factor 23 Levels in Hemodialysis Patients.
    Otsuki T; Utsunomiya K; Moriuchi M; Horikoshi S; Okamura M; Suzuki H; Okamura M; Maruyama N; Shibahara N; Abe M
    Nephron; 2018; 140(3):161-168. PubMed ID: 29991053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
    Iguchi A; Kazama JJ; Yamamoto S; Yoshita K; Watanabe Y; Iino N; Narita I
    Nephron; 2015; 131(3):161-6. PubMed ID: 26551233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of erythropoietin resistance and fibroblast growth factor 23 in dialysis patients: Results from the Japanese Dialysis Outcomes and Practice Patterns Study.
    Usui T; Zhao J; Fuller DS; Hanafusa N; Hasegawa T; Fujino H; Nomura T; Zee J; Young E; Robinson BM; Nangaku M
    Nephrology (Carlton); 2021 Jan; 26(1):46-53. PubMed ID: 32743932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
    Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
    Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal anaemia treatment in haemodialysis patients in the Central and Eastern European countries in everyday clinical practice follow-up.
    Malyszko J; Drozdz M; Zolkiewicz A; Rutkowski B
    Int Urol Nephrol; 2014 Jan; 46(1):71-82. PubMed ID: 23136027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K; Kairaitis L
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoietin Responsiveness in Hemodialysis Patients.
    Maruyama N; Otsuki T; Yoshida Y; Nagura C; Kitai M; Shibahara N; Tomita H; Maruyama T; Abe M
    Am J Nephrol; 2018; 47(6):406-414. PubMed ID: 29874654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
    J Ren Nutr; 2014 Jul; 24(4):261-7. PubMed ID: 24836401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis
.
    Umanath K; Greco B; Jalal DI; McFadden M; Sika M; Koury MJ; Niecestro R; Hunsicker LG; Greene T; Lewis JB; Dwyer JP
    Clin Nephrol; 2017 Mar; 87 (2017)(3):124-133. PubMed ID: 28128726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients.
    Shima H; Miya K; Okada K; Minakuchi J; Kawashima S
    BMC Res Notes; 2018 Jun; 11(1):363. PubMed ID: 29884226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.